Is Can-Fite BioPharma Ltd. (CANF) a Buy, Sell, or Hold?
AMEX : CANF
Can-Fite BioPharma Ltd.
$3.44 USD
-$0.12 (-3.37%)
- Volume
- 28.72K
- Average Volume
- 1.45M
- Market Capitalization
- $4.5M
- P/E Ratio
- -0.77
- Dividend Yield
- 0.00%
- Price Target
- $8.00
- Year High
- $14.00
- Year Low
- $2.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.46
Company Overview
AMEX
Motti Farbstein
Biotechnology
Healthcare
CANF
5
IL
USD
Liquidity Metrics
0.01
3.46
3.46
2.02
0.00
Sales & Valuation
$408.21K
18.70
0.68
-0.85
-8.31
Profitability
-$0.0802
-$9.91M
-2426.67%
-2426.67%
-201.06%
-103.30%
P/E Metrics
-0.77
0.01
0.01
Analyst Price Target & Rating
$8.00
$8.00
$8.00
2/5
4 Analysts
-57.00%
Financial Health Scores
-27.78
2/9
$6.71M
$9.51M
$3.92M
-$9.95M
Key Metrics (TTM)
$2.1M
5.19
-0.21
3.46
-201.06%
-145.49%
-258.50%
-118.41%
0 days
Company Executives
| Name | Title |
|---|---|
| Sari Fishman | Vice President of Business Development |
| Stephen A. Harrison FACP | Member of Clinical Advisory Board & Consulting Chief Medical Officer |
| Motti Farbstein | Chief Executive Officer and Chief Financial & Operating Officer |
| Pnina Fishman | Founder, Chief Scientific Officer & Executive Chairperson |
Poll Results
No votes yet today — be the first to share your view!
About Can-Fite BioPharma Ltd. (AMEX:CANF) Stock
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a ... predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
2026-08-03 07:00:00
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the submission of a Phase 2 clinical study protocol to Bambino Gesù Children's Hospital in Rome, Italy, for the first clinical evaluation of Piclidenoson in patients with Lowe syndrome, a rare inherited genetic disorder with no approved disease-modifying therapies.
2026-07-20 07:00:00
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months
2026-07-14 07:00:00
Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Australian Patent Office has allowed Patent Application No.
2026-07-06 07:00:00
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced completion of enrolment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis.
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients
2026-07-01 10:13:06
Can-Fite BioPharma Ltd. (NYSE:CANF) on Wednesday said its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint, with updated follow-up data showing durable overall survival in a subset of heavily pretreated patients.
Wall Street is Watching These Biotechs
2026-07-01 09:32:00
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy
2026-07-01 07:00:00
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months Ramat Gan, Israel, July 01, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes.
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
2026-06-26 07:00:00
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan, Israel, June 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Japan Patent Office has allowed Japanese Patent Application No.
Frequently Asked Questions
-
What is the current Can-Fite BioPharma Ltd. (CANF) stock price?
-
Can-Fite BioPharma Ltd.(AMEX:CANF) stock price is $3.44 in the last trading session. During the trading session, CANF stock reached the peak price of $14 while $2.56 was the lowest point it dropped to. The percentage change in CANF stock occurred in the recent session was --3.37% while the dollar amount for the price change in CANF stock was -$0.12.
-
CANF's industry and sector of operation?
-
The AMEX listed CANF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CANF?
-
Sari Fishman | Vice President of Business Development
Stephen A. Harrison FACP | Member of Clinical Advisory Board & Consulting Chief Medical Officer
Motti Farbstein | Chief Executive Officer and Chief Financial & Operating Officer
Pnina Fishman | Founder, Chief Scientific Officer & Executive Chairperson
| -
How many employees does CANF have?
-
Number of CANF employees currently stands at 5. CANF operates from 26 Ben Gurion Street, Ramat Gan, None 5257346, IL.
-
Link for CANF official website?
-
Official Website of CANF is: https://www.canfite.com
-
How do I contact CANF?
-
CANF could be contacted at phone #972 3 924 1114 and can also be accessed through its website. CANF operates from 26 Ben Gurion Street, Ramat Gan, None 5257346, IL.
-
How many shares of CANF are traded daily?
-
The average number of CANF shares traded daily for last 3 months was 1.45M.
-
What is the market cap of CANF currently?
-
The market value of CANF currently stands at $4.5M with its latest stock price at $3.44